文献速递眼底病与葡萄膜炎

YAG激光玻璃体消融术与假YAG玻璃体消融术治疗症状性玻璃体混浊:一项随机临床试验

YAG Laser Vitreolysis vs Sham YAG Vitreolysis for Symptomatic Vitreous Floaters: A Randomized Clinical Trial.
PubMed 文献 · JAMA Ophthalmol · 2017-01-01

这项单中心、设盲、假手术对照的随机临床试验纳入52例(52眼)因玻璃体后脱离导致症状性Weiss环的患者,比较YAG激光玻璃体消融术与假手术治疗6个月的主观和客观改善。YAG组主观症状改善54%,对照组为9%,差异45%(95%CI 25%-64%,P<.001);YAG组10点视觉干扰评分改善3.2,对照组为0.1,差异-3.0(95%CI -4.3至-1.7,P<.001)。作者认为YAG激光玻璃体消融术在主观上改善了Weiss环相关症状,并在客观上改善了Weiss环外观,但需要更大规模、更长随访的确证性研究来提高对这些结果的信心。

要点

  • YAG组主观症状改善54%,对照组为9%,差异45%(95%CI 25%-64%,P<.001)。
  • YAG组19例(53%)报告症状显著或完全改善,对照组为0例(差异53%,95%CI 36%-69%,P<.001)。
  • YAG组10点视觉干扰评分改善3.2,对照组为0.1,差异-3.0(95%CI -4.3至-1.7,P<.001)。

核心结论

  • YAG激光玻璃体消融术在主观上改善了Weiss环相关症状,并在客观上改善了Weiss环外观。
  • 更大规模、更长随访的确证性研究可能提高对这些结果的信心。

研究设计与样本

  • 单中心、设盲、假手术对照的随机临床试验,2015年3月25日至2016年8月3日在一家私立眼科诊所进行。
  • 纳入52例患者的52眼(YAG激光组36例,对照组16例),患者有玻璃体后脱离导致的症状性Weiss环。

主要发现

  • YAG组报告主观症状改善54%,对照组为9%,差异45%(95%CI 25%-64%,P<.001)。
  • YAG组10点视觉干扰评分改善3.2,对照组为0.1,差异-3.0(95%CI -4.3至-1.7,P<.001)。
  • YAG组19例(53%)报告症状显著或完全改善,对照组为0例,差异53%(95%CI 36%-69%,P<.001)。
  • 与对照组相比,YAG组NEI VFQ-25在一般视力(差异16.3,95%CI 0.9-31.7,P=.04)、周边视力(差异11.6,95%CI 0.8-22.4,P=.04)、角色困难(差异17.3,95%CI 8.0-26.6,P<.001)和依赖(差异5.6,95%CI 0.5-10.8,P=.03)方面改善。
  • YAG组最佳矫正视力变化-0.2个字母,对照组为-0.6个字母,差异0.4(95%CI -6.5至5.3,P=.94)。

关键数值与推荐

  • YAG激光组平均年龄(标准差)为61.4(8.0)岁,假手术组为61.1(6.6)岁。
  • 两组不良事件无差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 更大规模、更长随访的确证性研究可能提高对这些结果的信心。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Vitreous floaters are common and can worsen visual quality. YAG vitreolysis is an untested treatment for floaters. OBJECTIVE: To evaluate YAG laser vitreolysis vs sham vitreolysis for symptomatic Weiss ring floaters from posterior vitreous detachment. DESIGN, SETTING, AND PARTICIPANTS: This single-center, masked, sham-controlled randomized clinical trial was performed from March 25, 2015, to August 3, 2016, in 52 eyes of 52 patients (36 cases and 16 controls) treated at a private ophthalmology practice. INTERVENTIONS: Patients were randomly assigned to YAG laser vitreolysis or sham YAG (control). MAIN OUTCOMES AND MEASURES: Primary 6-month outcomes were subjective change measured from 0% to 100% using a 10-point visual disturbance score, a 5-level qualitative scale, and National Eye Institute Visual Functioning Questionnaire 25 (NEI VFQ-25). Secondary outcomes included objective change assessed by masked grading of color fundus photography and Early Treatment Diabetic Retinopathy Study best-corrected visual acuity. RESULTS: Fifty-two patients (52 eyes; 17 men and 35 women; 51 white and 1 Asian) with symptomatic Weiss rings were enrolled in the study (mean [SD] age, 61.4 [8.0] years for the YAG laser group and 61.1 [6.6] years for the sham group). The YAG laser group reported greater symptomatic improvement (54%) than controls (9%) (difference, 45%; 95% CI, 25%-64%; P < .001). In the YAG laser group, the 10-point visual disturbance score improved by 3.2 vs 0.1 in the sham group (difference, -3.0; 95% CI, -4.3 to -1.7; P < .001). A total of 19 patients (53%) in the YAG laser group reported significantly or completely improved symptoms vs 0 individuals in the sham group (difference, 53%; 95% CI, 36%-69%, P < .001). Compared with sham, NEI VFQ-25 revealed improved general vision (difference, 16.3; 95% CI, 0.9-31.7; P = .04), peripheral vision (difference, 11.6; 95% CI, 0.8-22.4; P = .04), role difficulties (difference, 17.3; 95% CI, 8.0-26.6; P < .001), and dependency (difference, 5.6; 95% CI, 0.5-10.8; P = .03) among the YAG laser group. Best-corrected visual acuity changed by -0.2 letters in the YAG laser group and by -0.6 letters in sham group (difference, 0.4; 95% CI, -6.5 to 5.3; P = .94). No differences in adverse events between groups were identified. CONCLUSIONS AND RELEVANCE: YAG laser vitreolysis subjectively improved Weiss ring-related symptoms and objectively improved Weiss ring appearance. Greater confidence in these outcomes may result from larger confirmatory studies of longer duration. TRIAL REGISTRATION: clinicaltrials.gov NCT02897583.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Shah CP, Heier JS. YAG Laser Vitreolysis vs Sham YAG Vitreolysis for Symptomatic Vitreous Floaters: A Randomized Clinical Trial. JAMA Ophthalmol. 2017. PMID: 28727887. doi:10.1001/jamaophthalmol.2017.2388

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。